ClinicalTrials.gg
RecruitingNCT07136779Updated Sep 3, 2026

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

A Phase 1/2 interventional study of VBC101 in Participants With Advanced Solid Tumor Malignancies, sponsored by VelaVigo Bio Inc. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by VelaVigo Bio Inc (part of VelaVigo Cayman Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
310
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC101.

Read the detailed description

Protocol Version:V1.3 Version Date:2026-04-20

02

Conditions studied

  • Participants With Advanced Solid Tumor Malignancies
03

In context

Lead sponsor

VelaVigo Bio Inc is the lead sponsor of 5 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant must meet all of the following inclusion criteria to be eligible to participate in this trial:

  • 1. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.
  • 2. or cytologically confirmed unresectable advanced/ solid tumor that has or progressed on or after standard systemic treatments, or is intolerable with standard treatment, or for which no standard treatment is available
  • 3. At least one as assessed by the investigator according to v1.1criteria
  • 4. Male or female adults (defined as ≥ 18 years of age)
  • 5. performance status 0-1
  • 6. Has ≥ 50% by either ECHO or MUGA within 28 days before enrollment.
  • 7. greater than 12 weeks
  • 8. Archived tumor tissue sample available or able to undergo a fresh collection.
  • 9. Adequate organ and bone marrow function
  • 10. Participants must meet the minimum requirements before the first dose of drug

Exclusion criteria

Exclusion Criteria:

1. Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment, except for alopecia, neuropathy, or skin pigmentation changes. Participants with chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the study investigator and the Sponsor's Medical Monitor.

  • 2. Known or suspected , or spinal cord compression, unless the condition has been treated, asymptomatic, and has been stable without requiring escalating doses of (equivalent to ≤10 mg/day prednisone) or anti-convulsant medications for at least four weeks prior for the first dose of drug.
  • 3. Prior treatment with an ADC targeting EGFR and/or cMet (including VBC101)
  • 4. Prior treatment with any ADC carrying a TOP1i payload (including prior VBC101).
  • 5. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    Phase 1 (Dose Escalation and Backfill),Phase 2(Dose optimization and Cohort Expansion)

    Drug: VBC101

Interventions

  • DrugVBC101

    VBC101

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLT) as defined in the protocol

    Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol

    Time frame: (DLT)From time of first dose of VBC101 to end of DLT period (approximately 21 days)

  2. Incidence of Serious Adverse Events

    Number of patients with serious adverse events by system organ class and preferred term

    Time frame: From time of Informed Consent to 30 days post last dose of VBC101

  3. Incidence of Adverse Events(AEs)

    Number of patients with adverse events by system organ class and preferred term

    Time frame: From time of Informed Consent to 30 days post last dose of VBC101

Secondary outcomes

  1. Objective Response Rate (ORR)

    The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)

    Time frame: From date of first dose of VBC101 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)

  2. Duration of Response (DoR)

    The time from date of first response until date of disease progression or last evaluable assessment (RECIST v1.1) in the absence of progression

    Time frame: From date of first dose of VBC101 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)

  3. Disease Control Rate (DCR) at 12 weeks

    The percentage of patients with confirmed CR or PR or having SD maintained (RECIST v1.1) for \>=11 weeks from first dose

    Time frame: From date of first dose of VBC101 up until progression, or the last evaluable assessment in the absence of progression (for each patient this is expected to be measured at 12 weeks)

  4. Progression free Survival (PFS)

    The time from first dose until RECIST 1.1 defined disease progression or death due to any cause

    Time frame: From date of first dose of VBC101 up until date of progression or death due to any cause (approximately 2 years)

  5. Overall Survival (OS)

    The time from the date of the first dose of study treatment until death due to any cause.

    Time frame: From date of first dose of VBC101 up until the date of death due to any cause (approximately 2 years)

  6. Pharmacokinetics of VBC101: Plasma PK concentrations

    Measurement of plasma concentrations of VBC101, total antibody and total unconjugated warhead

    Time frame: From date of first dose of VBC101 up until 30 days post last dose

  7. Pharmacokinetics of VBC101: Area under the concentration time curve (AUC)

    Measurement of PK parameters: Area under the concentration time curve (AUC)

    Time frame: From date of first dose of VBC101 up until 30 days post last dose

  8. Pharmacokinetics of VBC101: Maximum plasma concentration of the study drug (C-max)

    Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)

    Time frame: From date of first dose of VBC101 up until 30 days post last dose

  9. Pharmacokinetics of VBC101: Time to maximum plasma concentration of the study drug (T-max)

    Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)

    Time frame: From date of first dose of VBC101 up until 30 days post last dose

  10. Pharmacokinetics of VBC101: Half-life

    Measurement of PK parameters: Terminal elimination half-life (t 1/2)

    Time frame: From date of first dose of VBC101 up until 30 days post last dose

  11. Immunogenicity of VBC101: Anti-Drug Antibodies (ADA)

    Evaluating the number and percentage of patients who develop Anti-drug antibody (ADA) during treatment

    Time frame: From date of first dose of VBC101 up until 30 days post last dose

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jul 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Aug 22, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2028
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136779
Lead sponsor
VelaVigo Bio Inc
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Sep 23, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Sep 3, 2026

Study contacts

Chen Li
Contact
chen.li@velavigo.com
+86 13681943496

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion